



Linking PAH Exposure to Health Outcomes Using a Primary Human *In Vitro* Respiratory Model

Susan C. Tilton, Ph.D.


Associate Professor

OSU/PNNL SRP Project Lead

Environmental and Molecular Toxicology Department


Oregon State University

NIEHS SRP Risk e-Learning Webinar Series
From Cells to Solutions – Session II
January 16, 2026





Center for the Science, Technology and Emerging Health Risks of PAHs




Identification, measurement, and toxicity of PAHs
The mission of the Oregon State University Superfund Research Center is to identify Polycyclic Aromatic Hydrocarbons (PAHs) in the environment, to characterize their toxicity, and to determine what levels of those chemicals in the environment are safe for human health.






Center for the Science, Technology, and Emerging Health Risks of PAHs





Center for the Science, Technology, and Emerging Health Risks of PAHs





Polycyclic Aromatic Hydrocarbons (PAHs)



- Planar compounds of benzene rings
- Occurring naturally in coal, creosote, etc.
- Formed during incomplete combustion
- Connected with many adverse health effects
 - Carcinogenicity, Immunotoxicity, Reproductive/Developmental
 - Inhalation is a primary route of exposure



Prevalence of Alkylated PAHs

Anderson Project

Developing and Evaluating
Technology to Measure
PAH Fate and Exposures




- Passive sampling devices were deployed in the air and water at a Brownsfield creosote site
- In all cases, the alkylated PAHs were more abundant than unsubstituted PAHs

Prevalence of Alkylated PAHs

Anderson Project

Developing and Evaluating
Technology to Measure
PAH Fate and Exposures




- Quantitative data on personal exposure to polycyclic aromatic hydrocarbons (PAHs) in 162 silicone wristbands
- Several 2-3 ring alkylated PAHs were measured in high abundance depending on season

Polycyclic aromatic hydrocarbons (PAHs): Chemical characteristics

16 priority EPA PAHs (ATSDR, 2005)



- Toxicity
- Potential for human exposure
- Frequency of occurrence at hazardous waste sites
- Available information
- Include probable and known human carcinogens



Polycyclic aromatic hydrocarbons (PAHs): Chemical characteristics




- Broader class of polycyclic aromatic compounds
 - >1500 chemicals total
 - Diverse structural features
 - Includes both unsubstituted and substituted forms
 - O-, N-, S-, CH₃-
 - Little data available on sources, exposure, toxicity, mechanisms

Example of some naphthalene alkylated series





Alkyl-PAH Toxicity



Many alkyl-PAHs cause toxicity at concentrations lower than unsubstituted PAHs across multiple endpoints

Asterisks () indicate that the alkylated PAH caused a statistically significant response at a concentration lower than its corresponding parent compound*




				benzo[a]pyrene	
		*		7-methyl benzo[a]pyrene	2
				10-methylbenzo(a)pyrene	
		*		6-methylbenzo(a)pyrene	1
		*		7,10-dimethylbenzo(a)pyrene	
*		*		9-methylbenzo(a)pyrene	0
		*		8-methylbenzo(a)pyrene	
				pyrene	
*				1-methyl pyrene	-1
				Chrysene	
*	*	*		3-methyl chrysene	
*	*	*	*	5-methyl chrysene	
*	*	*		6-methyl chrysene	
*				6-ethyl chrysene	
*				phenanthrene	
*		*		retene	
				Benzo[c]phenanthrene	
*	*	*		1,12-dimethylbenzo(c)phenanthrene	
		*		2-methylbenzo(c)phenanthrene	
*				3-methylbenzo(c)phenanthrene	
*	*	*		4-methylbenzo(c)phenanthrene	
*		*		5,8-dimethylbenzo(c)phenanthrene	
*	*	*		5-methylbenzo(c)phenanthrene	
				dibenz[a,h]anthracene	
*	*	*		3-methyl dibenz[a,h]anthracene	
				benz[a]anthracene	
*		*	*	1-methyl benz[a]anthracene	
*	*	*		7,12-dimethyl benz[a]anthracene	
*		*	*	3-methyl cholanthrene	
*	*	*	*	8,9,11-trimethyl benz[a]anthracene	
				3,9-dimethylbenz(a)anthracene	
*		*		2,9-dimethylbenz(a)anthracene	
*				6,8-dimethylbenz(a)anthracene	
		*		7-methylbenz(a)anthracene	
*		*		8-methylbenz(a)anthracene	
				9-methylbenz(a)anthracene	
*		*		10-methylbenz(a)anthracene	
*		*		6-methylbenz(a)anthracene	
*				3-methylbenz(a)anthracene	
*				4-methylbenz(a)anthracene	
*				5-methylbenz(a)anthracene	
Cytotoxicity	Oxidative Stress	Mitochondrial Damage	DNA Damage		

3D Airway Organotypic Culture Model

Air-Liquid Interface (ALI) Culture Models:

Benefits of model:

- Primary human bronchial epithelial cells (HBECs)
- 3D structure
- Metabolic and mitotic activity
- Multi-cellular communication and cell signaling
- More accurately reflects exposure at tissue interfaces
- Better recapitulates *in vivo* response





3D Airway Organotypic Culture Models


Benefits of model:

- Primary human bronchial epithelial cells (HBECs)
- 3D structure
- Metabolic and mitotic activity
- Multi-cellular communication and cell signaling
- More accurately reflects exposure at tissue interfaces
- Better recapitulates *in vivo* response


Air-Liquid Interface (ALI) Culture Models:



3D Disease Model




Co-Culture with Immune Cells



Utilization of New Approach Methodologies (NAMs) in environmental health


Translational Toxicology Pipeline

- Development of complex in vitro systems
 - Multicellular
 - Metabolically competent
- Replace traditional animal models
- Allow translation/extrapolation to humans
- Improve understanding of key events leading to adverse outcomes in humans
- More predictive of toxicity and disease





Develop a quantitative PBPK/dosimetry model for 3D culture systems

- Develop pharmacokinetic model to extrapolate *in vitro* toxicity to adverse health outcomes *in vivo*
- Understanding role of metabolism in for PAH toxicity in 3D model
- Compare to environmentally-relevant exposure concentrations for assessing risk




Develop a quantitative PBPK/dosimetry model for 3D culture systems

- Develop pharmacokinetic model to extrapolate *in vitro* toxicity to adverse health outcomes *in vivo*
- Understanding role of metabolism in for PAH toxicity in 3D model
- Compare to environmentally-relevant exposure concentrations for assessing risk





PAH metabolism in 3D model



Develop a quantitative PBPK/dosimetry model for 3D culture systems

- Develop pharmacokinetic model to extrapolate *in vitro* toxicity to adverse health outcomes *in vivo*
- Understanding role of metabolism in for PAH toxicity in 3D model
- Compare to environmentally-relevant exposure concentrations for assessing risk




Quantify PAH metabolism and distribution into different 3D model compartments across dose and time

Develop parameters for dosimetry model


Develop a quantitative PBPK/dosimetry model for 3D culture systems

- Develop pharmacokinetic model to extrapolate *in vitro* toxicity to adverse health outcomes *in vivo*
- Understanding role of metabolism in for PAH toxicity in 3D model
- Compare to environmentally-relevant exposure concentrations for assessing risk


PBPK Model Building



Disposition of BAP in 3D model




Mucus



Cells







Media



Plastic


Total recovery of BAP:



Can we observe PAH metabolite formation?

- 3D cells exposed to BAP 0-48 hrs total hours
 - BAP 10 nmoles
 - Collect media, mucus, and cell fractions
- Ethyl acetate extraction on media, mucus, and cell fractions
 - DBC used as internal standard
- Identify parent and metabolites by UPLC
 - Standards for 14 BAP metabolites
 - Fluorescence detection

BAP Metabolism




Standards


Metabolite	Steps from Parent
4,5-epoxide	1
6-OH	1
3-OH	1,2
1-OH	2
7-OH	2
9-OH	2
4,5-diol	2
7,8-diol	2
9,10-diol	2
7,8-quinone	3
3,6-quinone	4
6,12-quinone	4
tetrol	4
1,6-quinone	5

Formation of metabolites

BAP Treated Media Sample at 24 hours




➔ Identified metabolite




Formation of metabolites


Recovery of BAP only:




Recovery of BAP + Metabolites:



Combined total BAP metabolites




Increase in 7,8-diol and tetrols over time show potential for continuous formation of BPDE




DNA Damage Mediated by PAHs in 3D HBEC

- Detect single strand breaks by PAHs
- Trapping agents halt NER leaving SSBs
 - Hydroxyurea (HU)
 - 1-β-D-arabinofuranosyl cytosine (AraC)




DNA damage (Comet Chip) by BAP at 24 hours





Formation of metabolites

Recovery of BAP only:




Recovery of BAP +
Metabolites:





Formation of metabolites

Recovery of BAP only:





Recovery of BAP +
Metabolites:




Building a Dosimetry Model in ALI HBEC

- Describe BAP ADME
 - Absorption into cells (KA)
 - Permeation through cells (PAL)
 - Partitioning into media (PLM)
 - Elimination
 - Metabolism in cells (CLC)
 - Volatilization from media (KE)




Building a Dosimetry Model in ALI HBEC

- Good fit for BAP in media
 - Very little makes it to media
- Good fit for BAP in cells
- Overestimate metabolism after 8 hours
 - Data represents a minimum amount of metabolism
 - Metabolites begin to appear at 4 hours





Building a Dosimetry Model in ALI HBEC

HBEC-ALI Culture Model:




PBPK Model Output:





Building a Dosimetry Model in ALI HBEC

- Develop a PBPK model for quantitative extrapolation of toxicity across models
- Establish a better understanding of metabolic competency of an organotypic airway model
- Improves application for predictive toxicology
- Future studies will assess dosimetry for other PAHs and apply to IVIVE for translation of toxicity

HBEC-ALI Culture Model:



PBPK Model Output:





Overall: These studies support the use of ALI-HBECs as a competent NAM for PAH toxicity assessment and for predicting toxicity in humans.

3D Airway Organotypic Culture Models


Benefits of model:

- Primary human bronchial epithelial cells (HBECs)
- 3D structure
- Metabolic and mitotic activity
- Multi-cellular communication and cell signaling
- More accurately reflects exposure at tissue interfaces
- Better recapitulates *in vivo* response


Air-Liquid Interface (ALI) Culture Models:



3D Disease Model




Co-Culture with Immune Cells



3D Airway Organotypic Culture Model


- Benefits of model:
- Development of disease models (e.g. Asthmatic phenotype)
- Pathophysiology similar to allergic asthma
 - Mucociliary dysfunction
 - Airway remodeling
 - Mucus hypersecretion
 - Loss of barrier integrity





National Asthma Rates


- Climate Vulnerability Index allows us to visualize rates of adult asthma
 - 2021 data from CDC
 - Coloring shows National Vulnerability Percentile
 - Percentile is scaled where 100th percentile is the highest rate of asthma
- Oregon ranks 5th out of 51 states/districts
 - High vulnerability
- State rankings based on the median value of all census tract data within the state





Higher rates of asthmatic adults surrounding an exposure source suggests a need to better understand how combined stressors contribute to toxicity




- National asthma rate: ~8%
- Oregon ranks 5th out of 51 states/districts
 - High vulnerability
- Total asthma rate in Oregon: 11.2%
 - Children & Adults
- Areas surrounding the Portland Harbor Superfund site generally rank between 57th and 94th percentile
 - Adult asthma rate of 9-13%





3D respiratory model for asthma

- Normal primary human bronchial epithelial cells (HBEC)
 - Cultured at air-liquid interface to create 3D model
 - Cells differentiate
 - Comparable response to *in vivo* models
 - Can be cultured in presence of interleukin-13 to induce an asthma-like phenotype

Functional measure of Barrier Integrity



Mucus & Mucus Producing Cells




Periodic Acid-Schiff's Stain




A PAH mixture uniquely exacerbates barrier disruption in the IL-13 phenotype.

- Barrier integrity of airway epithelium maintains homeostasis and protects against environmental factors
- Barrier dysfunction can result in increased risk of chemical uptake and contribute to worsening chronic inflammation
- Toxicity Mix exposure caused further exacerbation of barrier disruption in the IL-13 phenotype, but had no impact in the normal phenotype
- This trend was not observed after exposure to BAP




Evaluating role of combined stressors contributing to toxicity

- Pulmonary inflammation associated with inflammation-based respiratory disease (e.g. asthma) is potential modifier and risk factor for chemical toxicity
 - May respond to chemical toxicity with altered susceptibility
 - Utilize lung cells from diseased donors or expressing diseased phenotype
- Utilize a macrophage-epithelial co-culture to effectively evaluate immune contribution to lung inflammation





Response to chemical toxicity in normal and asthmatic lung cells




Utilization of an *in vitro* co-culture model to evaluate PAH mixture toxicity

- Utilize a macrophage-epithelial co-culture to effectively evaluate immune contribution to lung inflammation
- In the respiratory system, induction of airway inflammation is orchestrated through signaling between airway epithelial cells and macrophages.
- Evaluate the combined contribution of airway epithelial-macrophage response to chemicals from wildfire smoke



Benefits of 3D *in vitro* models to evaluate PAH toxicity

- Application of integrated approaches for understanding chemical toxicity and prioritizing environmentally-relevant exposures
- Utilization of cell-based NAMs in combination with *in silico* approaches to develop quantitative methods for *in vitro* to *in vivo* translation
- Leveraging human-relevant systems to improve our understanding of toxicity to combined stressors and interindividual variability





Tilton Lab (current and past)

Victoria Colvin, PhD
Yvonne Chang, PhD
Brianna Rivera, PhD
Beth Siddens
Jamie Pennington
Kyle Burns
Reese Valdez

Collaborators

Kim Anderson, OSU
David Williams, OSU
Monica Maier, OSU
Jamie DeWitt, OSU

Mackenzie Allison
Leo Ramirez
Rubi Juarez Murguia
Audrey Biggertaff
Kelley Bastin


Bevin Engelward, MIT
Norah Owiti, MIT
Katrina Waters, PNNL
Jordan Smith, PNNL

Funding Sources:

Superfund Research Center P42 ES016465
PNW Center for Translational Environmental Health
Research P30 ES030287
NIEHS Training Grant T32 ES007060
Center for Alternatives to Animal Testing
Colgate-Palmolive Award for Alternative Methods
U.S. Department of Energy Contract DE-AC06-
76RL01830



Oregon State
University



PACIFIC
NORTHWEST
CENTER
—for—

Translational
Environmental
Health Research





Thank you

